Optimising Synchrotron Microbeam Radiation Therapy for Cancer Treatment

Grant number: 606614 | Funding period: 2010 - 2012

Completed

Abstract

Over 50% of cancer patients receive radiotherapy (RT). Tumour control using RT is limited by adverse normal tissue reactions. Unlike conventional RT machines, the Australian synchrotron has the capability to deliver strong radiation in very thin slices, termed microbeam RT (MRT). Tumour control has been obtained in animal models with a remarkable sparing of normal tissue using MRT. We will optimize MRT as a crucial step towards a potentially revolutionary cancer treatment.

Related publications (5)

Scholarly works icon

An evaluation of novel real-time technology as a tool for measurement of radiobiological and radiation-induced bystander effects

MJ Ibahim, JC Crosbie, P Paiva, Y Yang, M Zaitseva, PAW Rogers

2016-05-01

The xCELLigence real-time cell impedance system uses a non-invasive and label-free method to create a cell index that is a composi..

Scholarly works icon

In vitro study of genes and molecular pathways differentially regulated by synchrotron microbeam radiotherapy

Y Yang, JC Crosbie, P Paiva, M Ibahim, A Stevenson, PAW Rogers

2014-12-01

The aim of this study was to identify genes and molecular pathways differentially regulated by synchrotron-generated microbeam rad..

Scholarly works icon

An evaluation of dose equivalence between synchrotron microbeam radiation therapy and conventional broadbeam radiation using clonogenic and cell impedance assays

MJ Ibahim, JC Crosbie, Y Yang, M Zaitseva, AW Stevenson, PAW Rogers, P Paiva

2014-06-19

Background: High-dose synchrotron microbeam radiation therapy (MRT) has shown the potential to deliver improved outcomes over conv..

Scholarly works icon

Reference dosimetry at the Australian Synchrotron's imaging and medical beamline using free-air ionization chamber measurements and theoretical predictions of air kerma rate and half value layer

JC Crosbie, PAW Rogers, AW Stevenson, CJ Hall, JE Lye, T Nordström, SM Midgley, RA Lewis

2013-01-01

Purpose: Novel, preclinical radiotherapy modalities are being developed at synchrotrons around the world, most notably stereotacti..

Scholarly works icon

Genome-wide transcription responses to synchrotron microbeam radiotherapy

CN Sprung, Y Yang, HB Forrester, J Li, M Zaitseva, L Cann, T Restall, RL Anderson, JC Crosbie, PAW Rogers

2012-10-01

The majority of cancer patients achieve benefit from radiotherapy. A significant limitation of radiotherapy is its relatively low ..

University of Melbourne Researchers